COVID-19 Clinical Diagnostics and Testing Technology
COVID-19 Clinical Diagnostics and Testing Technology
复制标题
DOI：
10.1002/phar.2439
复制
发表时间：
2020-08-01
期刊：
影响因子：
4.1
通讯作者：
Figg, William D.
中科院分区：
文献类型：
--
作者：
Chau, Cindy H.;Strope, Jonathan D.;Figg, William D.
鉴于2019冠状病毒病（COVID-19）大流行的全球性质，疾病检测和扩大检测能力的需求仍然是关键的优先事项。本文综述了目前使用或正在开发的新型冠状病毒检测能力和方法学方面的技术进展。我们描述了当前严重急性呼吸综合征-冠状病毒2（SARS-CoV-2）检测的临床诊断和技术，包括分子和血清学检测方法，并指出其优点和局限性。用于分子诊断的核酸扩增技术仍然是病毒检测的金标准。我们强调了用于开发新型COVID-19诊断方法的替代分子检测技术。对SARS-CoV-2的抗体反应仍然知之甚少，需要对血清学检测进行适当的验证，以证明其准确性和临床实用性。为了控制这一流行病，我们必须通过改进临床诊断和检测技术以及提供这些工具，加快发展快速和广泛的检测。
Given the global nature of the coronavirus disease 2019 (COVID-19) pandemic, the need for disease detection and expanding testing capacity remains critical priorities. This review discusses the technological advances in testing capability and methodology that are currently used or in development for detecting the novel coronavirus. We describe the current clinical diagnostics and technology, including molecular and serological testing approaches, for severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) testing as well as address their advantages and limitations. Nucleic acid amplification technology for molecular diagnostics remains the gold standard for virus detection. We highlight alternative molecular detection techniques used for developing novel COVID-19 diagnostics on the horizon. Antibody response against SARS-CoV-2 remains poorly understood and proper validation of serology tests is necessary to demonstrate their accuracy and clinical utility. In order to bring the pandemic under control, we must speed up the development of rapid and widespread testing through improvements in clinical diagnostics and testing technology as well as access to these tools.